<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>188-THIAZIDE-DIURETICS-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THIAZIDE DIURETICS AND RELATED" code="C03-003" /></DRUG1>
<DRUG2>
<DRUG name="CALCIUM" rxcui="1895">
<ATC code="A12AA" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of hypercalcemia due to decrease of the urinary elimination of the calcium. </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>188-THIAZIDE-DIURETICS-AND-RELATED.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="THIAZIDE DIURETICS AND RELATED" code="C03-003" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of lithium with signs of overdose of lithium, as with a reduced sodium regimen (decrease of the urinary excretion of the lithium)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict monitoring of the plasma concentrations of lithium and adjustment of the dosage of the lithium.</COMMENT>
</INTERACTION>
</INTERACTIONS>
